Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3728 with concurrent chemoradiotherapy in locally advanced head and neck tumors
CTR20233304Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3728 in head and neck cancer (HNC), head and neck squamous cell carcinoma (HNSCC), head and neck glandular carcinoma (HNGC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Oct 2023; status: terminated.
02
Drugs
TQB3728
03
Conditions
head and neck cancer (HNC)head and neck squamous cell carcinoma (HNSCC)head and neck glandular carcinoma (HNGC)
Beyond the preview
Go deeper on CTR20233304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233304.